logo-loader

Futura Medical kicks off Phase III study on erectile dysfunction gel

Published: 12:07 19 Sep 2018 BST

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive's Andrew Scott they've begun a Phase III study for their MED2002 erectile dysfunction treatment, while the CSD500 erectogenic condom's received shelf life approval from regulators.

Barder says the MED2002 trial, which is expecting its first patients to enter study within the next month, will involve 1,000 patients with headline data expected by the end of 2019.

Futura Medical marks pivotal year with first meaningful revenue from Eroxon...

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company as it rolled out its innovative sexual health product, Eroxon, designed to treat erectile dysfunction. The over-the-counter availability of Eroxon distinguishes...

on 7/2/24